- SARS-CoV-2 PCR cycle threshold at hospital admission associated with Patient
 Mortality
- Jui Choudhuri¹*, Jamal Carter¹, Randin Nelson¹, Karin Skalina¹, Marika Osterbur-Badhey¹, Andrew
 Johnson², Doctor Goldstein¹, Monika Paroder¹, James Szymanski¹*
- 5 1-Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, N.Y.
- 6 2-Department of Medicine, Saint Vincent's Medical Center, Bridgeport CT USA
- 7 *These authors have equal contribution to the study and preparation of the manuscript
- 8 Address Correspondence to:
- 9 James Szymanski MD, MHA
- 10 Department of Pathology
- 11 Montefiore Medical Center/Albert Einstein College of Medicine
- 12 Bronx, NY
- 13 jszymans@montefiore.org

14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	Keywords: COVID-19, Coronavirus, Coronavirus 2019, PCR cycle threshold
26	
27	Financial Support: none

It is made available under a CC-BY-ND 4.0 International license .

29 ABSTRACT

30 Background:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cycle threshold (Ct) has been suggested
as an approximate measure of initial viral burden. The relationship of initial Ct at hospitalization and
patient mortality has not been thoroughly investigated.

34 Methods and findings

We conducted a retrospective study of SARS-CoV-2 positive, hospitalized patients from 3/26/2020 to 35 36 8/5/2020 who had SARS-CoV-2 Ct data within 48 hours of admission (n=1044). Only patients with 37 complete survival data discharged (n=774) or died in hospital (n=270), were included in our analysis. 38 Laboratory, demographic, and clinical data were extracted from electronic medical records. 39 Multivariable logistic regression was applied to examine the relationship of patient mortality with Ct 40 values while adjusting for established risk factors. Ct was analyzed as continuous variable and 41 subdivided into quartiles to better illustrate its relationship with outcome. Cumulative incidence curves 42 were created to assess whether there was a survival difference in the setting of the competing risks of 43 death versus patient discharge.

Mean Ct at admission was higher for survivors (28.6, SD=5.8) compared to non-survivors (24.8, SD=6.0,
P<0.001). Patients with lower Ct value on admission had higher odds ratio (0.91, Cl 0.89-0.94, p<0.001)
of in-hospital mortality after adjusting for age, gender, BMI, hypertension and diabetes. Patients with Ct
values in 3rd Quartile (Ct 27.4-32.8) and 4th Quartile (Ct >32.9) had lower odds of in-hospital death
(P<0.001). On comparing, Ct quartiles, mortality, BMI and GFR were significantly different (p<0.05)
between the groups. The cumulative incidence of all-cause mortality and discharge was found to differ
between Ct quartiles (Gray's Test P<0.001).

51 Conclusion:

It is made available under a CC-BY-ND 4.0 International license .

52 SARS-CoV-2 Ct was found to be an independent predictor of patient mortality. However, further study is
53 needed on how to best clinically utilize such information given the result variation due to specimen

- 54 quality, phase of disease, and the limited discriminative ability of the test.
- 55

56 AUTHOR SUMMARY

57 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has effected the entire world, 58 with approximately 23 million affected till date. Clinicians, researcher and scientists are making all 59 efforts to identify ways of diagnosis, predicting outcome and treatment modalities. The polymerase 60 chain reaction (rT-PCR) technology, is the standard test being used for the diagnosis and it gives an 61 additional value known as "cycle threshold" (Ct), which is the number of PCR cycles required to cross the 62 designated threshold and termed patient as positive for the infection. This Ct value is inverse of the viral 63 load in the patient and has been studied as indicator of outcome of infection. In this study we have 64 analyzed the Ct value as a predictor for mortality and compared it between different age and gender. 65 We found the Ct value significantly different between those who survived and those who died due to 66 the disease. However proper utilization of the Ct value needs further studies to be utilized in the clinical 67 setting and guide decision making.

- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75

It is made available under a CC-BY-ND 4.0 International license .

76 Introduction:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 is a novel betacoronavirus that first appeared in Wuhan, Hubei Province, China in late December 2019.(1) This virus has led to a global pandemic with over 23 million people infected worldwide with an overall mortality rate between 1.4% and 5%.(2, 3) It was declared a pandemic by the World Health Organization (WHO) on March 11, 2020.(4) While scientists, clinicians and researchers continue to grapple with the infection, the continuous in-flow of clinical data is helping to guide diagnostic, treatment and prognostic characteristics of the disease.

84 COVID-19 has wide-ranging clinical presentation, with 80% of cases being mild, 15% developing lower 85 respiratory tract disease such as pneumonia, and less than 5% developing severe illness. (5) For those 86 who progress to severe disease, the clinical course is insidious, with mild initial illness progressing to 87 major complications in the second week.(5) The requirement for mechanical ventilation ranges from 18 88 to 33%, approximately 20% of hospitalized patients die of disease.(6-10) Multiple factors have been 89 studied in association with disease severity, such as D-dimer, lymphopenia, obesity, hypertension and 90 diabetes mellitus (DM) and there is still a continuous search for a reliable marker to predict disease 91 aggressiveness (11-16)

92 Real-time reverse-transcriptase (rRT-PCR) is a major modality of diagnosing infection. The cycle number 93 (Ct) derived is the amplification required for the target viral gene to cross a threshold value and is 94 inversely related to the viral load.(17) Kawase et al. have defined Ct as the cycle number when the 95 sample fluorescence exceeds a set above the calculated background fluorescence.(18) There is limited 96 literature exploring the association of Ct and disease mortality, and there has been variability in the 97 findings.(10, 17, 19, 20) The objective of this study is to examine the relationship between SARS-CoV-2 98 cycle threshold at hospital admission and its relationship to patient outcome.

It is made available under a CC-BY-ND 4.0 International license .

\sim	\sim
- u	ч
0	J

100

101 Methodology:

102 In this retrospective observational study we included all hospitalized patients at Montefiore Medical 103 Center between 3/26/2020 and 8/5/2020 with a positive SARS-CoV-2 nasopharyngeal swab specimen on 104 the Panther Fusion System (Hologic, Inc.) that was collected within 48 hours of admission. Subjects 105 under the age of 18, current inpatients, those with initial SARS-CoV-2 testing on the Fusion system >48 106 hours after admission, or missing BMI were excluded from the analysis. (Figure 1) The patient information 107 and data including test results and comorbidities were collected retrospectively from electronic medical 108 records. Vital sign data included in the study, represented the first recorded vitals in the hospital records 109 during admission and the biochemical and other parameters were indexed as the closest result within 110 48 hours to SARS-CoV-2 testing. The study was approved by the Albert Einstein College of Medicine 111 Institutional Review Board.

112 Viral testing was performed on the Panther Fusion System (Hologic, Inc.) rRT-PCR platform, which has 113 received Emergency Use Authorization with the Food and Drug Administration (FDA). All testing was 114 performed according to the manufacturer's instructions. The basic steps of the assay include sample 115 lysis, nucleic acid capture, elution transfer, and multiplex RT-PCR where analytes are simultaneously 116 amplified and detected. Results are reported as positive or negative depending on detectable 117 amplification. The instrument also generates a Ct value. For the purpose of this study, Ct was divided 118 into quartiles (Q1, Q2, Q3 and Q4) for grouping samples and studying the significance of viral load as an 119 indirect marker. Low Ct corresponded to higher viral load.

Statistical Analysis: Demographic and baseline group differences were assessed using chi-square tests, 2 sample Student t-tests, and for non-normally distributed data, the Mann-Whitney U test. The

It is made available under a CC-BY-ND 4.0 International license .

122 correlation between variables was assessed using the Kendall rank correlation method due to non-123 parametric data. The relationship between in-hospital mortality, cycle guartile, clinical risk factors, and 124 biomarkers was modeled using logistic regression. Model covariate selection was based on literature 125 review of identified SARS-CoV-2 survival risk factors. Model fit was assessed using the Hosmer and 126 Lemeshow test which found p>0.05, thus not detecting evidence of poor fit. Multicollinearity was 127 evaluated using variance inflation factors. Model discriminative ability was validated by calculating 128 bootstrapped AUC. Cumulative incidence curves were created to assess whether there was a survival 129 difference by cycle threshold quartile. This approach was used to account for the competing risks of in-130 hospital mortality versus patient discharge. A sensitivity analysis was carried out which assessed for 131 patterns in missing data, study result sensitivity to covariate selection, and time period selected.(S1-S4) 132 Analyses were performed using R version 3.6.2. A *p*-value <0.05 was considered statistically significant.

133 **RESULTS**

134

A total of 1,044 patients met study inclusion criteria, of these 774 (74.1%) survived to discharge and 270 (25.9%) expired. Fig 1 In our cohort, 55.6% (580) patients were males and 44.4% (464) females with a mean age of 65.2 years (SD 15.37) and a mean BMI of 29.6 (SD 7.4). A history of hypertension (HTN) and Diabetes (DM) was present in 64.1% (629) and 40.8% (400), respectively. The majority of patients had group O blood-type, 46.5% (410), followed by group A blood-type, 31.6% (278).

140

141 Ct at admission was positively correlated with patient survival (r=0.22, p<0.001) (Figure 2). To better 142 illustrate the magnitude of the effect, Ct was divided into quartiles (Q1, Q2, Q3 and Q4). The Q1 group 143 consisted of cycle numbers <22.9, Q2 was cycle numbers between 23.0 and 27.3, Q3 was between 27.4 144 and 32.8 and Q4 was >32.9. It was noted that mortality was significantly different between the four 145 groups, with highest mortality in those with lowest Ct (Q1=41.4%) and lowest in the group with highest

It is made available under a CC-BY-ND 4.0 International license .

146	Ct (Q4=13.2%) (p<0.001). Table 1. The association of cycle quartile and patient mortality held when
147	stratified across age groups (Fisher's exact test p<0.05 for all groups.) Fig 3. The cycle quartile was
148	compared between age groups and gender. Fig 4. The cumulative incidence of hospital discharge varied
149	across the cycle quartile (Gray's Test P<0.001), as did the patient mortality (Gray's test P<0.001). Fig 5.
150	
151	Table 1. Study Characteristics by COVID-19 PCR Cycle Quartile

152

		Cohort characteristics stratified by PCR Cycle Quartile								
	Overall Cohort	Q1	Q2	Q3	Q4	-				
		(<22.9)	(23.0-27.3)	(27.4-32.8)	(>32.9)					
n (%)	1044	263	263	260	258	p value				
Mortality, n (%)	270 (25.9)	109 (41.4)	84 (31.9)	43 (16.5)	34 (13.2)	<0.001				
LOS, median [IQR]	6.0 [3.0, 11.0]	6.0 [3.0, 12.0]	6.0 [3.0, 9.2]	6.0 [3.0, 9.7]	6.0 [4.0, 9.7]	0.33				
Male , n (%)	580 (55.6)	153 (58.2)	154 (58.6)	134 (51.5)	139 (53.9)	0.29				
Age, mean (SD)	65.2 (15.3)	69.4 (15.0)	66.6 (14.6)	62.6 (14.3)	62.2 (17.5)	0.52				
BMI, mean (SD)	29.6 (7.4)	27.8 (7.6)	30.3 (7.8)	30.2 (6.8)	30.1 (7.1)	<0.001				
eGFR, mean (SD)	63.1 (34.5)	55.9 (33.9)	60.7 (35.6)	67.8 (33.4)	69.0 (33.2)	<0.001				
LDH, median [IQR]	403 [303, 548]	373 [270, 537]	393 [306,549]	419[321,582]	413 [306, 538]	0.03				
Initial PO2, mean (SD)	93.0 (5.8)	94.4 (7.5)	94.7 (7.6)	94.8 (6.6)	94.6 (7.2)	0.48				
Initial DBP*, mean (SD)	68.4 (14.9)	66.2 (15.8)	66.3 (15.2)	70.3 (14.2)	70.8 (13.6)	<0.001				
Hx of DM [Yes], n (%)	400 (40.8)	113 (44.5)	98 (38.0)	100 (39.7)	89 (41.0)	0.49				
Hx of HTN [Yes], n (%)	629 (64.1)	180 (70.9)	163 (63.2)	157 (62.3)	129 (59.4)	0.06				
ABO Type, n (%)		Ш		I	1					
Туре А	278 (31.6)	85 (36.6)	77 (33.6)	57 (26.9)	59 (29.2)					
Type AB	41 (4.7)	8 (3.5)	11 (4.8)	11 (5.2)	11 (5.3)	0.24				
Туре В	152 (17.3)	29 (12.6)	43 (18.8)	43 (20.3)	37 (17.7)	-				
Type O	410 (46.5)	109 (47.2)	98 (42.8)	101 (47.6)	102 (48.8)	4				

153

154

155 A multivariate logistic model was created describing the impact of cycle quartile, patient age, gender,

156 BMI, and the comorbidities of hypertension and diabetes on patient survival. With the first cycle quartile

157 (Q1) set as reference the adjusted odds of patient mortality decreased as cycle quartile increased,

It is made available under a CC-BY-ND 4.0 International license .

158	becoming significant in Q3 (aOR 0.34, Cl 0.22-0.52, P<0.001) and Q4 (aOR 0.26, Cl 0.16-0.42, p<0.001).
159	Table 2. Male gender was found to confer a heightened risk of COVID-19 in-hospital mortality (aOR 1.88,
160	Cl 1.37-2.59, p<0.01). Likewise increased age, BMI, and a history of diabetes were all found to increase
161	adjusted odds of in hospital mortality. Interestingly comorbid hypertension was found significant in
162	univariable analysis but lost significance in the multivariable model.

163

Table 2. Logistic Regression table of In-Hospital Mortality

164

In-Hospita	l Mortality	Expired	Survived	Odds ratio (univariable)	Odds ratio (multivariable)
Age	Mean (SD)	72.4 (12.9)	62.8 (15.4)	1.05 (1.04-1.06, p<0.001)	1.05 (1.04-1.06, p<0.001)
	Q1	109 (40.4)	154 (19.9)	-	-
Cruch	Q2	84 (31.1)	179 (23.1)	0.66 (0.46-0.95, p=0.024)	0.68 (0.46-1.00, p=0.050)
Cycle Quartile	Q3	43 (15.9)	217 (28.0)	0.28 (0.18-0.42, p<0.001)	0.34 (0.22-0.52, p<0.001)
	Q4	34 (12.6)	224 (28.9)	0.21 (0.14-0.33, p<0.001)	0.26 (0.16-0.42, p<0.001)
	F	97 (35.9)	367 (47.4)	-	-
Gender	Μ	173 (64.1)	407 (52.6)	1.61 (1.21-2.15, p=0.001)	1.88 (1.37-2.59, p<0.001)
BMI	Mean (SD)	29.2 (8.2)	29.8 (7.2)	0.99 (0.97-1.01, p=0.301)	1.03 (1.01-1.06, p=0.006)
	No	139 (52.1)	442 (61.9)	-	-
DM	Yes	128 (47.9)	272 (38.1)	1.50 (1.13-1.99, p=0.005)	1.38 (1.00-1.90, p=0.048)
HTN	No	74 (27.7)	278 (38.9)	-	-
	Yes	193 (72.3)	436 (61.1)	1.66 (1.23-2.27, p=0.001)	1.03 (0.72-1.47, p=0.868)

165

The use of cycle threshold as a reported parameter predictive of inpatient mortality is limited by variation in sample collection, sample run variation, and the lack of a high-performing cutoff value Fig 6 and 7. The variation in optimal cutoff was assessed by bootstrapping with 1000 replications with ideal

It is made available under a CC-BY-ND 4.0 International license .

169 cutpoint determined using Youden's index. The cutpoint which maximized Youden's statistic was found
170 to be 26 (Cl 26-27). At this cutpoint, the testing set (out-of-bag) sensitivity was found to be 0.65 (Cl 0.58171 0.72) and specificity was 0.64 (Cl 0.57 0.69). The area under the curve (AUC) was 0.68 (Cl 0.63-0.71),
172 thus the discriminative ability of the test to predict inpatient mortality was limited.

173

174 **DISCUSSION**

175

176 COVID-19 has a highly-variable severity, thus identifying patients at risk of more aggressive disease is 177 critical for triage and early management. While BMI, history of hypertension, and DM have been 178 aggressively evaluated, there are recent studies which have looked at rRT-PCR Ct as an indicator of 179 mortality or disease course.(10, 21) While it is difficult to utilize raw Ct values as a substitute for viral 180 burden without the production of an appropriate standard curve or normalization to an internal 181 housekeeping gene, attempts have been made to examine just this utility.(22) Previous studies which 182 have looked at Ct or viral loads for disease aggressiveness have found differing results, which may be 183 attributed to variability within the temporal course of infection. (10, 20, 23) Some studies have reported 184 that peak load of the virus in upper respiratory tract specimens was expected during early stages of 185 infection and in the pre-symptomatic stage, while others have found the peak to be approximately two 186 weeks after the onset of symptoms even extending into the 3rd or 4th week of illness.(24-26)

2heng et al. described increased viral load in respiratory samples in patients with a more aggressive disease course as compared to those with milder disease and therefore found that it could be used as a possible indicator of prognosis.(25) Similar results have been reported by Liu et al.(27) This correlation was not seen in relation to the viral load in stool samples.(25) Chen et al. reported that patients in the intensive care unit (ICU) continued to remain positive for COVID-19 infection longer than those who

It is made available under a CC-BY-ND 4.0 International license .

were not in the ICU.(28) Rao et al. in their systematic review of 18 studies reported an association between the viral load (or cycle number) and clinical outcome.(17) There was only one among 18 studies reviewed that looked at cycle number and mortality and found lower cycle number value associated with increased risk of mortality.(17, 29) Our results demonstrate a similar pattern as we found Ct values correlated inversely with mortality and low Ct increased the odds ratio for mortality compared to higher Ct.

198 According to Rao et al. 73% of the studies which looked at Ct in hospitalized patients found an 199 association between Ct and disease aggressiveness, however, none of the studies which identified this 200 association involved non-hospitalized patients. (17) Argyropoulos et al. in their research did report higher 201 viral loads in non-hospitalized patients with an inverse relation between viral load and duration of 202 symptoms and its severity. (20) The available literature suggests that recruitment of hospitalized patients 203 might be a potential bias of analyzing the more severely ill among the overall infected population. 204 Argyropoulos et al. did not find any association between viral load and length of hospital stay. (20) Our 205 results also did not find any correlation with length of hospital stay for hospitalized patients.

206 Comparing our cohort of New York patients with findings by Magleby et al. it was noted that both 207 showed a statistically significant difference between age groups and the Ct. (10) However, we also noted 208 a difference related to male gender, which was not noted in their analysis.(10) Magleby et al. reported 209 that patients with high viral loads were at increased risk of myocardial infarction and acute kidney 210 injury.(10) We reached a similar inference regarding GFR and the Ct (viral load) showing that patient 211 with high viral load had poorer GFR. Rao et al. found elevated LDH corresponded to low cycle numbers 212 (higher viral load) and reported it as an important marker which showed consistent results in all the four 213 studies in which it was included.(17) LDH was significantly different between patients of the different Ct

It is made available under a CC-BY-ND 4.0 International license .

quartiles in our study as well. Contrary to studies which have found ABO blood group as an indicator of
disease severity, we were not able to identify such a correlation. (30)

216 Our study suggests that Ct can be used as an independent indicator of mortality--this corroborates 217 previously reported data. (24) While Ct has been observed to be an important indicator of viral infection. 218 it is influenced by the assay used and factors that can affect the amplification efficiency.(30) While 219 studies like ours have helped identify independent markers which may in future help clinicians predict 220 outcome, we are still cautious about its reliability for several important reasons. Firstly, most studies, 221 including ours, have performed their analysis based on a single patient result. It is well understood that 222 the testing is greatly limited by the quality of sample and its associated collection. This variability might 223 be overcome through multiple patient sampling to improve the robustness of Ct as a tool. Additionally, 224 some studies have reported contrary results with respect to viral load and disease outcome which might 225 imply that the temporal relation of viral load and the Ct interpretation may depend on stage of 226 infection. Literature on Ct is also limited by the fact that studies have primarily focused on hospitalized 227 patients and the larger cohort of non-hospitalized patients and those with milder disease forms of 228 infection have not been analyzed thoroughly enough.

While our study included a large and diverse cohort of patients due to its geographical location, some of the limitations included inability to analyze significance of race/ethnicity due to missing data from the medical records. This study could not explore viral load in non-hospitalized patients, and mild or asymptomatic patients were not initially swabbed due to hospital policy.

Ct-based risk stratification or interpretation is also limited by the absence of absolute or constant Ct cutoff values. The Ct value ranges can vary widely by platform and are impacted by amplicon length, target
region, PCR cycling protocols, and other reaction conditions which alter the overall PCR efficiency even
when the same target gene is amplified. (4) Adopting the Ct value for clinical judgement is limited by the

It is made available under a CC-BY-ND 4.0 International license .

237	scope of error due to multiple factors including interpretation by the examiner.(4) Additionally, since
238	testing is primarily upon nasopharyngeal swabs there is much greater variability from one collection to
239	another in addition to variability between patient disease states.(4) Therefore, even with our promising
240	results, the clinical applications of our findings would require further investigation to determine the
241	ultimate value of Ct interpretation.
0.40	
242	
243	Conclusion:
244	SARS-CoV-2 cycle threshold at admission was found to be an independent predictor of in-patient
245	mortality. However, further study is needed on how to best clinically utilize such information given the
246	result variation due to specimen quality, phase of disease, and the limited discriminative ability of the
247	test.
248	
249	
250	
251	REFERENCES
252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267	 Yuen KS, Ye ZW, Fung SY, Chan CP, Jin DY. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci. 2020;10:40. Organization WH. 2020 [Available from: https://covid19.who.int/. Al-Tawfiq JA, Leonardi R, Fasoli G, Rigamonti D. Prevalence and fatality rates of COVID-19: What are the reasons for the wide variations worldwide? Travel Med Infect Dis. 2020;35:101711. Chang MC, Hur J, Park D. Interpreting the COVID-19 Test Results: A Guide for Physiatrists. Am J Phys Med Rehabil. 2020;99(7):583-5. Deming ME, Chen WH. COVID-19 and Lessons to Be Learned from Prior Coronavirus Outbreaks. Ann Am Thorac Soc. 2020;17(7):790-4. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372-4.

Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al.

268

8.

269 Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York 270 City: a prospective cohort study. Lancet. 2020;395(10239):1763-70. 271 Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al. 9. 272 Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New 273 York: retrospective case series. BMJ. 2020;369:m1996. 274 Magleby R, Westblade LF, Trzebucki A, Simon MS, Rajan M, Park J, et al. Impact of 10. 275 SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with 276 Coronavirus Disease 2019. Clin Infect Dis. 2020. 277 Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts 11. 278 disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 279 2020;5(1):33. 280 Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of 12. 281 COVID-19 - A systematic review. Life Sci. 2020;254:117788. 282 Yu B, Li X, Chen J, Ouyang M, Zhang H, Zhao X, et al. Evaluation of variation in D-dimer 13. 283 levels among COVID-19 and bacterial pneumonia: a retrospective analysis. J Thromb 284 Thrombolysis. 2020. 285 Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. Am J 14. 286 Hypertens. 2020;33(5):373-4. 287 15. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in 288 progress. Diabetes Res Clin Pract. 2020;162:108142. 289 16. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, 290 pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 291 2020;14(4):303-10. 292 17. Rao SN, Manissero D, Steele VR, Pareja J. A Narrative Systematic Review of the 293 Clinical Utility of Cycle Threshold Values in the Context of COVID-19. Infect Dis Ther. 2020. 294 Kawase J, Asakura H, Kurosaki M, Oshiro H, Etoh Y, Ikeda T, et al. Rapid and Accurate 18. 295 Diagnosis Based on Real-Time PCR Cycle Threshold Value for the Identification of 296 Campylobacter jejuni, astA Gene-Positive Escherichia coli, and eae Gene-Positive E. coli. Jpn J 297 Infect Dis. 2018;71(1):79-84. 298 Feikin DR, Fu W, Park DE, Shi Q, Higdon MM, Baggett HC, et al. Is Higher Viral Load in 19. 299 the Upper Respiratory Tract Associated With Severe Pneumonia? Findings From the PERCH 300 Study. Clin Infect Dis. 2017;64(suppl_3):S337-S46. 301 Argyropoulos KV, Serrano A, Hu J, Black M, Feng X, Shen G, et al. Association of Initial 20. 302 Viral Load in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients with 303 Outcome and Symptoms. Am J Pathol. 2020. 304 Pujadas E, Chaudhry F, McBride R, Richter F, Zhao S, Wajnberg A, et al. SARS-CoV-2 21. 305 viral load 306 predicts COVID-19 307 mortality. Lancet Respir Med 2020. 2020;S2213-2600(20):30354-4 308 22. Aguino-Jarguin G. The raw Ct values from RT-PCR detection are not viral load 309 quantitation units. Clin Infect Dis. 2020. 310 To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of 23. 311 viral load in posterior oropharyngeal saliva samples and serum antibody responses during 312 infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565-74. 313 24. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in 314 Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2020;382(12):1177-9. 315 Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease 25. 316 severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 317 2020: retrospective cohort study. BMJ. 2020;369:m1443. Page | 13

318 26. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral 319 shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672-5.

Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical
indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life
Sci. 2020;63(3):364-74.

323 28. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with 324 COVID-19 in Shanghai, China. J Infect. 2020;80(5):e1-e6.

325 29. Huang JT, Ran RX, Lv ZH, Feng LN, Ran CY, Tong YQ, et al. Chronological Changes of 326 Viral Shedding in Adult Inpatients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020.


327 30. Bustin SA, Mueller R. Real-time reverse transcription PCR (qRT-PCR) and its potential

- use in clinical diagnosis. Clin Sci (Lond). 2005;109(4):365-79.
- 329

330 FIGURE CAPTIONS

- **Figure 1**. Study Cohort
- **Figure 2.** Correlation Matrix. On top is the (absolute) value of the Kendall correlation, the
- Asterix indicates degree of statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001. On bottom, there are bivariate scatterplots, with a linear regression line.
- Figure 3. Stacked bar graph of Mortality by PCR Cycle Quartile and Age group. *Fisher's exact
 test used.
- **Figure 4.** Cycle Number and Mortality by Age and Gender
- **Figure 5.** Cumulative Incidence function of COVID-19 Mortality vs Discharge by Initial
- 340 COVID PCR Quartile
- 341
- **Figure 6.** Scatterplot of averaged value of repeated samples versus absolute cycle number
- difference between replicates. The solid line indicates the mean absolute replicate difference, andthe dashed line marks 2 standard deviations from the mean.
- **Figure 7.** (Panel A): Receiver Operating characteristic (ROC) curve of Inpatient Mortality by
- 346 Cycle Threshold value; (**Panel B**): Density plot of Bootstrapped Youden's index cutoffs (1500
- 347 replications); (**Panel C**): Sensitivity and Specificity Plot of Mortality by PCR Threshold value
- 348
- 349
- 350
- 351
- 352
- 353
- 354
- 355
- 356
- 357


It is made available under a CC-BY-ND 4.0 International license .



It is made available under a CC-BY-ND 4.0 International license .

Figure 2. Correlation Matrix. On top is the (absolute) value of the Kendall correlation, the

- 400 Asterix indicates degree of statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001. On
- 401 bottom, there are bivariate scatterplots, with a linear regression line.




It is made available under a CC-BY-ND 4.0 International license .

- . . .

Figure 3. Stacked bar graph of Mortality by PCR Cycle Quartile and Age group. *Fisher's exact

417 test used.


It is made available under a CC-BY-ND 4.0 International license .



Mortality by Age Group and PCR Cycle Quartile

Expire Surviv


It is made available under a CC-BY-ND 4.0 International license .



COVID PCR Cycle Number and Mortality by Age and Gender

Figure 5. Cumulative Incidence function of COVID-19 Mortality vs Discharge by Initial
 COVID PCR Quartile

It is made available under a CC-BY-ND 4.0 International license .




COVID-19 Mortality vs Discharge by Initial PCR cycle Quartile

Figure 6. Scatterplot of averaged value of repeated samples versus absolute cycle number

difference between replicates. The solid line indicates the mean absolute replicate difference, and

the dashed line marks 2 standard deviations from the mean.




SARS-CoV-2 PCR Replicates

It is made available under a CC-BY-ND 4.0 International license .

483 **Figure 7.** (**Panel A**): Receiver Operating characteristic (ROC) curve of Inpatient Mortality by

484 Cycle Threshold value; (**Panel B**): Density plot of Bootstrapped Youden's index cutoffs (1500

485 replications); (**Panel C**): Sensitivity and Specificity Plot of Mortality by PCR Threshold value




It is made available under a CC-BY-ND 4.0 International license .


491 SUPPLEMENTARY MATERIAL

- 492
- 493

494 **S1. (Left Panel)**: Barchart of the proportions of missing values. (**Right Panel**): all existing

- 495 combinations of missing values (Red) and non-missing values (Blue) with the pattern frequency
- 496 represented by small horizontal bars with the number involved indicated.
- 497
- 498
- 499





It is made available under a CC-BY-ND 4.0 International license .

510

511 S2. Sensitivity Analysis: examining the effect of selected time period on model results. Time

512 period has been divided into quarters based on PCR testing totals

513 514

> Period 1 Period 2 Period 3 Period 4 **Odds Odds Odds Odds** Ratio CI CI Ratio CI **Predictors** р Ratio р Ratio CI р р S S S S 0.01 0.00 0.00 0.00 0.11 <0.00 (Intercept) 0.13 0.04 0.036 0 0.04 0.028 _ 1 1 1.60 0.81 0.05 0.70 1.02 1.05 1.03 1.01 0.00 < 0.00 <0.00 <0.00 1.03 1.05 1.08 1.06 Age _ _ _ _ 1 1 1 3 1.05 1.08 1.09 1.11 0.89 0.67 1.36 1.30 0.56 Gender [M] 1.18 2.67 0.005 2.55 1.71 0.108 0.006 _ _ _ _ 8 2.10 5.00 5.26 3.30 0.99 0.97 1.03 0.99 0.71 BMI 1.01 1.04 1.08 1.03 0.102 0.12 0.003 _ _ _ 3 1.05 1.09 1.07 1.14 0.90 0.85 0.86 0.85 0.05 < 0.00 <0.00 Cycle 0.95 0.9 0.91 0.9 0.001 _ _ Threshold 3 1 1 1.00 0.95 0.96 0.94 Observatio 261 261 261 261 ns

515

516 517

518

519 520

521 522

523 524 525

526

527 528 529

530 531

532 533

534

535 536

537

538

539 540

541

It is made available under a CC-BY-ND 4.0 International license .

- 543
- 544

545 S3. Sensitivity Analysis: examining the effect of covariate selection on study findings

	Model 1		Model 2			Model 3			Model 4			Model 5			
Predicto rs	0 R	CI	р	O R	CI	р	O R	CI	p	0 R	CI	p	0 R	CI	р
Cycle Thresho ld	0 9 1	0.87 	<0 .0 01	0 9 1	0.88 0.95	<0 .0 01	0. 9	0.87 0.94	<0 .0 01	0 9 2	0.89 0.95	<0 .0 01	0 9 1	0.89 0.94	<0 .0 01
Age	1 0 4	1.01 _ 1.06	0. 00 2	1 0 4	1.02 - 1.06	<0 .0 01	1. 0 5	1.03 1.07	<0 .0 01	1 0 4	1.02 - 1.05	<0 .0 01	1 0 3	1.02 - 1.05	<0 .0 01
Gender [M]	2 2 6	1.30 _ 3.94	0. 00 4	2 0 1	1.27 - 3.20	0. 00 3	2. 0 8	1.34 	0. 00 1	2 0 8	1.40 _ 3.09	<0 .0 01	1 9 2	1.33 _ 2.79	0. 00 1
BMI	1 0 3	0.99 _ 1.07	0. 14 1	1 0 2	0.99 - 1.06	0. 18 7	1. 0 3	1.00 - 1.06	0. 07 3	1 0 4	1.01 _ 1.07	0. 01 8	1 0 3	1.00 - 1.05	0. 06 2
Pulse Ox	0 9 4	0.90 _ 0.98	0. 00 3	0 9 4	0.90 0.97	0. 00 1	0. 9 2	0.89 0.96	<0 .0 01	0 9	0.87 	<0 .0 01	0 9	0.87 	<0 .0 01
DBP	0 9 4	0.92 0.96	<0 .0 01	0 9 3	0.92 - 0.95	<0 .0 01	0. 9 4	0.92 0.95	<0 .0 01	0 9 4	0.93 0.96	<0 .0 01	0 9 4	0.93 0.96	<0 .0 01
eGFR	0 9 9	0.98 - 1.00	0. 06 7	0 9 9	0.98 1.00	0. 03 1	0. 9 9	0.98 1.00	0. 01 3	0 9 9	0.98 _ 0.99	<0 .0 01	0 9 9	0.98 _ 0.99	<0 .0 01
HTN [Yes]	0 7 1	0.38 - 1.33	0. 28 2	0 8 4	0.49 	0. 53 8	0. 8 1	0.49 	0. 39 1	0 9 2	0.59 	0. 70 6	1 0 1	0.66 	0. 96 4
DM [Yes]	1 8 2	1.05 	0. 03 3	1 6 7	1.05 	0. 03 1	1. 7	1.09 _ 2.65	0. 01 9	1 2 8	0.86 _ 1.89	0. 22 2	1 3 3	0.92 - 1.93	0. 12 9
NLR	1 0 4	1.01 - 1.08	0. 00 9	1 0 4	1.01 _ 1.07	0. 00 7	1. 0 4	1.01 _ 1.07	0. 00 8	1 0 3	1.01 _ 1.06	0. 01 8	1 0 3	1.01 _ 1.06	0. 00 8
Troponi n	1 4 6	0.54 _ 3.98	0. 45 8	1 3 8	0.52 - 3.65	0. 51 8	1. 5 3	0.51 _ 4.59	0. 44 6	1 9 9	0.66 _ 6.04	0. 22 3			
LDH 25 ABO	1	1.00 - 1.00 0.32	0. 03 7 0.	1	1.00 - 1.00 0.32	<0 .0 01 0.	1	1.00 1.00	<0 .0 01						

It is made available under a CC-BY-ND 4.0 International license .

546 547	[AB]	· - 0 3.7	89 3 2	0	_ 3.31	95 5			
548 549 550 551	ABO [B]	9 0 0.2 - 6 1.3	22	8	0.43 - 1.56	0. 54 4			
552 553 554 555 556	ABO [O]	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	01	2 0 5 6	0.34 	0. 02 7			
557 558 559 560	Ddimer	$\begin{array}{ccc} 1 & 1.0 \\ \cdot & - \\ 0 & - \\ 7 & 1.1 \end{array}$	00						
561 562	Observ ations	52	9		656		791	881	974
562 563 564	R ² Tjur AIC	0.4 414			0.419 533.21		0.422 596.58	0.376 720.259	0.367 798.314

It is made available under a CC-BY-ND 4.0 International license .

- **S4.** Sensitivity Analysis: examining the effect of covariate selection on study findings.

-

		Model	6	Model 7			Model 8			Model 9				Model 10		
Predictors	OR	CI	р	OR	CI	р	OR	CI	р	OR	СІ	р	OR	CI	р	
Cycle Threshold	0.9 1	0.89 _ 0.94	<0.00 1	0.9 1	0.89 - 0.94	<0.00 1	0.92	0.89 – 0.95	<0.00 1	0.9 1	0.89 – 0.94	<0.00 1	0.9 1	0.88 – 0.93	<0.00 1	
Age	1.0 3	1.02 - 1.05	<0.00 1	1.0 3	1.01 _ 1.04	<0.00 1	1.03	1.02 – 1.05	<0.00 1	1.0 4	1.03 – 1.05	<0.00 1	1.0 5	1.04 – 1.06	<0.00 1	
Gender [M]	2.0 1	1.39 _ 2.91	<0.00 1	2.0 1	1.39 _ 2.90	<0.00 1	2.01	1.40 – 2.90	<0.00 1	2.1	1.47 – 3.01	<0.00 1	1.7 9	1.28 – 2.48	0.001	
BMI	1.0 2	0.99 - 1.05	0.141	1.0 2	0.99 - 1.05	0.123	1.02	0.99 – 1.05	0.121	1.0 2	1.00 – 1.05	0.114	1.0 2	1.00 – 1.04	0.072	
Pulse Ox	0.8 9	0.87 	<0.00 1	0.8 9	0.87 	<0.00 1	0.89	0.87 – 0.92	<0.00 1	0.8 9	0.87 – 0.92	<0.00 1	0.8 9	0.87 – 0.92	<0.00 1	
DBP	0.9 4	0.93 - 0.96	<0.00 1	0.9 4	0.93 - 0.96	<0.00 1	0.94	0.93 – 0.95	<0.00 1	0.9 4	0.93 – 0.95	<0.00 1				
eGFR	0.9 9	0.98 _ 0.99	<0.00 1	0.9 9	0.98 _ 0.99	<0.00 1	0.99	0.98 – 0.99	<0.00 1							
HTN [Yes]	0.9 9	0.66 _ 1.50	0.971	1.0 7	0.72 - 1.60	0.736										
DM [Yes]	1.3 1	0.91 _ 1.90	0.146													
Observatio ns	976				976		1006		1040				1041			
R ² Tjur	0.36				0.358		0.355		0.341				0.225			
AIC		808.41	6		808.527			825.485		857.24				968.337		

It is made available under a CC-BY-ND 4.0 International license .

- • •